PaxVax Acquires the FDA-Approved Typhoid Vaccine Vivotif

July 28th, 2014 PaxVax Inc. a specialty vaccine company focused on travel and biodefense today announced that it has acquired the oral typhoid vaccine Vivotif® from Crucell Switzerland AG as well as its manufacturing facility in Thörishaus near Bern Switzerland. Additionally PaxVax is acquiring marketing sales and distribution capabilities in select markets including the United States and certain other assets …